CASI Pharmaceuticals Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio1.542.810.563.7124.15
P/B Ratio23.693.950.361.043.53
Price/Tangible Book27.184.270.561.555.35
Enterprise Value Ratios
EV/Revenue1.482.400.402.5120.66
Profitability & Returns
Return on Equity (ROE)-3.02%-0.58%-0.46%-0.34%-0.48%
Return on Assets (ROA)-0.38%-0.18%-0.14%-0.17%-0.18%
Return on Capital Employed (ROCE)-2.28%-0.43%-0.33%-0.28%-0.28%
Leverage & Solvency Ratios
Debt/Equity11.960.880.020.020.03
Liquidity Ratios
Current Ratio1.093.554.324.709.28
Quick Ratio0.862.453.784.438.90
Efficiency Ratios
Asset Turnover0.440.400.370.230.13
Inventory Turnover1.651.263.947.703.22
Yield & Distribution Ratios
Earnings Yield-0.90%-0.28%-1.68%-0.33%-0.13%
FCF Yield-0.67%-0.21%-1.10%-0.32%-0.07%
Buyback Yield-0.15%0.02%0.00%-0.23%-0.15%